BioPharma DiveDoubao · 实盘不做把握 5/10不做原因:已被定价
北京时间·🕒 发布 21:00:00(美东 09:00)·⟳ 抓取 21:04:15 +4m15s·⚡ 决策 09-14 21:14:38 +10m23s·43.1 天前
FDA批准Scholar Rock首款肌肉靶向SMA新药Isembyld，盘前冲高26%后大幅回落
批准在2025年遭拒、8月换厂重报后已被市场高度预期，股价自2024年底约10美元涨至55美元、市值约67亿美元已计入约20亿美元峰值销售预期；盘前从+26%高点（约69.9美元）大幅回落至+4.4%（57.84美元），呈典型利好兑现派发，且标签新增意外骨折警告，做多风险收益比差；获批为真实利好不构成做空催化，故双向回避。
📄 原文BioPharma Dive↗ 原文
Scholar Rock SMA drug approved by FDA
BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive…
不做 Scholar Rock Holding Corporation（SRRK.US）
高度明牌的FDA首批批准：股价自2024年底约10美元涨至55美元、市值约67亿美元已计入Leerink约20亿美元峰值销售预期；盘前冲高+26%（69.85美元）后回落至+4.4%（57.84美元），利好兑现派发特征明显，且标签新增意外骨折警告、2天后FOMC放大波动，追多风险收益比差；获批为真实正面事件，不满足做空红线，故双向不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Isembyld获批是Scholar Rock首款药物商业化的实质里程碑，但属高度明牌事件：市值67亿美元已透支约20亿美元峰值销售预期，盘前冲高26%后回落至+4%并伴意外骨折警告，见光死特征明显，不追多；无强空催化亦不做空。
🔎 新鲜度:最早出现 2026-09-11 · 扩散 high · price-in 风险 high ↗
关键理由
- 获批消除最后监管不确定性，峰值销售预期约20亿美元并获价值上亿美元的PRV，但这些在股价从10美元升至55美元的过程中大部分已被定价
- 盘前高点69.85美元（+26%）回落至57.84美元（+4.4%），成交量集中在高位回落段，显示资金借确认利好派发
主要风险
- 标签新增意外骨折风险警告，可能压制处方渗透和市场对峰值销售的预期
- FOMC利率决议在2天后，高波动未盈利生物科技股对利率情绪敏感，事件驱动持仓风险加大
反向证据
- 做多前查反向 · 来源 web · 日期 2026-09-14 · 影响 weakens
处方信息含此前未披露的骨折风险警告（Leerink称意外），叠加盘前+26%回落至+4%，削弱追多逻辑
检索:apitegromab label fracture warning / SRRK approval sell the news risks 原文 ↗
先例如何影响了这次决策
对本次决策的影响:因缺乏高相似对齐先例且盘前已大幅派发，直接支持AVOID而非追多
方向:未在本轮联网构建可核验的同类生物科技FDA批准先例面板，不用外部先例数字定幅度
涨幅量级:样本不足，不设止盈止损幅度；以盘前实际价格行为（+26%至+4%的冲高回落）作为最直接的定价证据
形态:本案自身盘前轨迹即呈现典型sell-the-news/见光死形态：批准确认后高位放量回落
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 17 ms
{"result": "search_processed_events:agent query=`apitegromab 上市 批准 脊髓性肌萎缩 | scholar rock apitegromab isembyld fda approval sma | scholar rock srrk fda approve muscle-targeted sma drug september 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是 - stock_quote 成功 stock_tools HTTP · 248 ms
{
原文全文
展开原文 · 9,792 字
Scholar Rock SMA drug approved by FDA | BioPharma Dive
Skip to main content
CONTINUE TO SITE ➞
Don't miss tomorrow's biopharma industry news
Let BioPharma Dive's free newsletter keep you informed, straight from your inbox.
Daily Dive
M-F
Commercialization Weekly
Every Wednesday
Gene Therapy Weekly
Every Thursday
Emerging Biotech Weekly
Every Tuesday
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Informa TechTarget
|
Healthcare Dive
MedTech Dive
PharmaVoice
Xtelligent Pharma Life Sciences
Explore our brands
An Informa TechTarget Publication
Search
People also ask
Loading questions...
An article from
Scholar Rock SMA drug approved by FDA
Isembyld is the first “muscle-targeted” treatment for the disease and, in clinical testing, helped improve motor function in people on standard therapies.
Published Sept. 14, 2026
Ben Fidler
Lead Editor
Share
Copy link
Email
LinkedIn
X/Twitter
Facebook
Print
License
Add us on Google
The FDA approved Scholar Rock's Isemblyd for spinal muscular atrophy on Sept. 11, 2026.
Courtesy of Scholar Rock
The Food and Drug Administration has approved a new kind of medication for the rare genetic disease spinal muscular atrophy.
Called apitegromab and to be sold as Isembyld, the treatment on Friday was
cleared for use alongside existing targeted therapies
in adults with SMA as well as children at least 2 years of age. For a typical SMA patient, the drug will have an annual list price of about $310,000 per year, executives revealed on a Monday conference call. Costs will vary person-to-person based on a patient’s weight and insurance coverage.
Isembyld’s clearance will once again change the treatment landscape for a potentially lethal disease that had no approved medicines as recently as a decade ago.
SMA is an inherited condition that causes progressive weakness and is typically fatal in its most severe form, which affects infants. It’s one of the most common rare diseases and is believed to impact as many as 10,000 to 25,000 children and adults in the U.S., according to the
non-profit SMA foundation
.
Prior to 2016, there weren’t any treatments available that could change the course of SMA. Medical care was more focused on supportive therapy and symptom management. Since then, though, the FDA has approved a
gene-targeting drug from Biogen
, a one-time
gene therapy from Novartis
and an
oral medication from Roche
. All three can keep babies alive when they might have died otherwise, grow healthily and avoid using a machine to help them breathe.
Still, those three drugs have mixed effects on motor function, leading to an eventual decline and providing room for a therapy that can alter that outcome.
Isembyld
could become that option. The drug blocks a protein, myostatin, that limits muscle growth. When tested alongside standard therapy, Isembyld showed it could
significantly improve motor function
compared to typical care alone.
Scholar Rock’s findings in late 2024 caused its share price, which had hovered around $10 apiece for multiple years, to take off. The company then overhauled its management team, built a sales force and prepped for a launch. Its new leaders made clear Scholar Rock’s intentions to grow into a large, independent company. Analysts at the firm Leerink Partners have predicted that Isembyld could bring in around $2 billion in peak annual sales
Yet Isembyld’s clearance has been held up by issues observed at a manufacturing facility that conducts “fill-finish” services for the company. Those problems
led the FDA to reject Isembyld last September
and for Scholar Rock to spend much of the last year coming up with an alternative production plan. In August, for instance, the company
removed that facility
from its application and added an alternate plant that met FDA standards. That change forced Scholar Rock to submit a new request in Europe, too.
That plan has now paid off with the company’s first drug approval. In its statement, Scholar Rock referred to Isembyld as the first “muscle-targeted” treatment for SMA and a “therapeutic breakthrough.” And Kenneth Hobby, the president of the advocacy group Cure SMA, noted in the statement that the clearance grants access to a “broad population” of people with the disease.
Improving motor function “is a significant unmet need that must be addressed with urgency,” Hobby said in Scholar Rock’s statement.
The prescribing information included a warning that Isembyld might increase the risk of bone fractures. That warning was “unexpected,” as fractures hadn’t previously been disclosed, wrote Leerink Partners analyst Basma Radwan. Still, they didn’t lead any participants to stop treatment and affected patients with “pre-existing risk factors,” she wrote.
Upper respiratory tract infections, vomiting, viral infections and headaches were among the other side effects linked to treatment.
Scholar Rock was awarded a “priority review” voucher that can speed up drug evaluations. Those vouchers can also be sold for nine-figure sums.
Recommended Reading
Scholar Rock SMA drug rejected by FDA over manufacturing concerns
By
Ben Fidler
•
Sept. 23, 2025
From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
By
Jonathan Gardner
•
Oct. 5, 2020
Add us on Google
Share
Copy link
Email
LinkedIn
X/Twitter
Facebook
Print
License
Filed Under:
FDA
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Editors' picks
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive
//
Emerging biotech
Biotech startups are built on venture capital. Track funding rounds here.
Six biotechs raised over $700 million in combined venture funding this week, though two of those companies — Solstice Oncology and Encoded Therapeutics — accounted for the bulk of the total.
By Gwendolyn Wu, Ben Fidler, Ned Pagliarulo and Julia Himmel •
Updated Sept. 11, 2026
Adeline Kon / BioPharma Dive/BioPharma Dive
Deep Dive
//
Patent thickets
Drug patents protect pharma profits. Track when they’ll expire.
BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.
By Jonathan Gardner •
Updated Aug. 4, 2026
Keep up with the story. Subscribe to the BioPharma Dive free daily newsletter
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Company Announcements
View all
|
Post a press release
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New B…
From Schrödinger, Inc.
September 09, 2026
FDA Approves Tablet Form of Zanubrutinib for All Approved Indications
From BeOne Medicines
September 09, 2026
NeuroGT Announces FDA Clearance of Investigational New Drug Application for NGT-104, an AAV9 G…
From NeuroGT
September 03, 2026
ACTO Achieves Veeva Gold Product Partner Status, Following a Nearly Decade-Long Collaboration …
From ACTO
September 02, 2026
Editors' picks
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive
//
Emerging biotech
Biotech startups are built on venture capital. Track funding rounds here.
Six biotechs raised over $700 million in combined venture funding this week, though two of those companies — Solstice Oncology and Encoded Therapeutics — accounted for the bulk of the total.
By Gwendolyn Wu, Ben Fidler, Ned Pagliarulo and Julia Himmel •
Updated Sept. 11, 2026
Adeline Kon / BioPharma Dive/BioPharma Dive
Deep Dive
//
Patent thickets
Drug patents protect pharma profits. Track when they’ll expire.
BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.
By Jonathan Gardner •
Updated Aug. 4, 2026
Latest in FDA
FDA places partial hold on Biohaven’s epilepsy drug
By Delilah Alvarado
FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders
By Kristin Jensen
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
By Jonathan Gardner
FDA OKs Takeda, Protagonist drug for rare blood cancer
By Delilah Alvarado
This website is owned and operated by
Informa TechTarget
,
a global network that informs, influences and connects the world's technology buyers and sellers.
© 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. An Informa PLC company.
Privacy policy
|
Terms of use
|
Take down policy
|
Cookie Preferences / Do Not Sell
Skip to main content
CONTINUE TO SITE ➞
Don't miss tomorrow's biopharma industry news
Let BioPharma Dive's free newsletter keep you informed, straight from your inbox.
Daily Dive
M-F
Commercialization Weekly
Every Wednesday
Gene Therapy Weekly
Every Thursday
Emerging Biotech Weekly
Every Tuesday
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Informa TechTarget
|
Healthcare Dive
MedTech Dive
PharmaVoice
Xtelligent Pharma Life Sciences
Explore our brands
An Informa TechTarget Publication
Search
People also ask
Loading questions...
An article from
Scholar Rock SMA drug approved by FDA
Isembyld is the first “muscle-targeted” treatment for the disease and, in clinical testing, helped improve motor function in people on standard therapies.
Published Sept. 14, 2026
Ben Fidler
Lead Editor
Share
Copy link
X/Twitter
License
Add us on Google
The FDA approved Scholar Rock's Isemblyd for spinal muscular atrophy on Sept. 11, 2026.
Courtesy of Scholar Rock
The Food and Drug Administration has approved a new kind of medication for the rare genetic disease spinal muscular atrophy.
Called apitegromab and to be sold as Isembyld, the treatment on Friday was
cleared for use alongside existing targeted therapies
in adults with SMA as well as children at least 2 years of age. For a typical SMA patient, the drug will have an annual list price of about $310,000 per year, executives revealed on a Monday conference call. Costs will vary person-to-person based on a patient’s weight and insurance coverage.
Isembyld’s clearance will once again change the treatment landscape for a potentially lethal disease that had no approved medicines as recently as a decade ago.
SMA is an inherited condition that causes progressive weakness and is typically fatal in its most severe form, which affects infants. It’s one of the most common rare diseases and is believed to impact as many as 10,000 to 25,000 children and adults in the U.S., according to the
non-profit SMA foundation
.
Prior to 2016, there weren’t any treatments available that could change the course of SMA. Medical care was more focused on supportive therapy and symptom management. Since then, though, the FDA has approved a
gene-targeting drug from Biogen
, a one-time
gene therapy from Novartis
and an
oral medication from Roche
. All three can keep babies alive when they might have died otherwise, grow healthily and avoid using a machine to help them breathe.
Still, those three drugs have mixed effects on motor function, leading to an eventual decline and providing room for a therapy that can alter that outcome.
Isembyld
could become that option. The drug blocks a protein, myostatin, that limits muscle growth. When tested alongside standard therapy, Isembyld showed it could
significantly improve motor function
compared to typical care alone.
Scholar Rock’s findings in late 2024 caused its share price, which had hovered around $10 apiece for multiple years, to take off. The company then overhauled its management team, built a sales force and prepped for a launch. Its new leaders made clear Scholar Rock’s intentions to grow into a large, independent company. Analysts at the firm Leerink Partners have predicted that Isembyld could bring in around $2 billion in peak annual sales
Yet Isembyld’s clearance has been held up by issues observed at a manufacturing facility that conducts “fill-finish” services for the company. Those problems
led the FDA to reject Isembyld last September
and for Scholar Rock to spend much of the last year coming up with an alternative production plan. In August, for instance, the company
removed that facility
from its application and added an alternate plant that met FDA standards. That change forced Scholar Rock to submit a new request in Europe, too.
That plan has now paid off with the company’s first drug approval. In its statement, Scholar Rock referred to Isembyld as the first “muscle-targeted” treatment for SMA and a “therapeutic breakthrough.” And Kenneth Hobby, the president of the advocacy group Cure SMA, noted in the statement that the clearance grants access to a “broad population” of people with the disease.
Improving motor function “is a significant unmet need that must be addressed with urgency,” Hobby said in Scholar Rock’s statement.
The prescribing information included a warning that Isembyld might increase the risk of bone fractures. That warning was “unexpected,” as fractures hadn’t previously been disclosed, wrote Leerink Partners analyst Basma Radwan. Still, they didn’t lead any participants to stop treatment and affected patients with “pre-existing risk factors,” she wrote.
Upper respiratory tract infections, vomiting, viral infections and headaches were among the other side effects linked to treatment.
Scholar Rock was awarded a “priority review” voucher that can speed up drug evaluations. Those vouchers can also be sold for nine-figure sums.
Recommended Reading
Scholar Rock SMA drug rejected by FDA over manufacturing concerns
By
Ben Fidler
•
Sept. 23, 2025
From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
By
Jonathan Gardner
•
Oct. 5, 2020
Add us on Google
Share
Copy link
X/Twitter
License
Filed Under:
FDA
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Editors' picks
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive
//
Emerging biotech
Biotech startups are built on venture capital. Track funding rounds here.
Six biotechs raised over $700 million in combined venture funding this week, though two of those companies — Solstice Oncology and Encoded Therapeutics — accounted for the bulk of the total.
By Gwendolyn Wu, Ben Fidler, Ned Pagliarulo and Julia Himmel •
Updated Sept. 11, 2026
Adeline Kon / BioPharma Dive/BioPharma Dive
Deep Dive
//
Patent thickets
Drug patents protect pharma profits. Track when they’ll expire.
BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.
By Jonathan Gardner •
Updated Aug. 4, 2026
Keep up with the story. Subscribe to the BioPharma Dive free daily newsletter
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Company Announcements
View all
|
Post a press release
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New B…
From Schrödinger, Inc.
September 09, 2026
FDA Approves Tablet Form of Zanubrutinib for All Approved Indications
From BeOne Medicines
September 09, 2026
NeuroGT Announces FDA Clearance of Investigational New Drug Application for NGT-104, an AAV9 G…
From NeuroGT
September 03, 2026
ACTO Achieves Veeva Gold Product Partner Status, Following a Nearly Decade-Long Collaboration …
From ACTO
September 02, 2026
Editors' picks
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive
//
Emerging biotech
Biotech startups are built on venture capital. Track funding rounds here.
Six biotechs raised over $700 million in combined venture funding this week, though two of those companies — Solstice Oncology and Encoded Therapeutics — accounted for the bulk of the total.
By Gwendolyn Wu, Ben Fidler, Ned Pagliarulo and Julia Himmel •
Updated Sept. 11, 2026
Adeline Kon / BioPharma Dive/BioPharma Dive
Deep Dive
//
Patent thickets
Drug patents protect pharma profits. Track when they’ll expire.
BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.
By Jonathan Gardner •
Updated Aug. 4, 2026
Latest in FDA
FDA places partial hold on Biohaven’s epilepsy drug
By Delilah Alvarado
FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders
By Kristin Jensen
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
By Jonathan Gardner
FDA OKs Takeda, Protagonist drug for rare blood cancer
By Delilah Alvarado
This website is owned and operated by
Informa TechTarget
,
a global network that informs, influences and connects the world's technology buyers and sellers.
© 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. An Informa PLC company.
Privacy policy
|
Terms of use
|
Take down policy
|
Cookie Preferences / Do Not Sell
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。